Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group

Chest
A. OrtqvistC Jean

Abstract

Comparison of efficacy and safety of sparfloxacin (Spfx) vs roxithromycin (ROXI) for treatment of community-acquired pneumonia (CAP). Multicenter, double-blind, randomized study. Twenty-three university and community hospitals in Scandinavia. Three hundred four adults (> or = 18 years of age) with CAP treated as outpatients (25%) or inpatients (75%). Randomization 1:1 to Spfx, 400 mg on day 1, then 200 mg once daily, or ROXI, 150 mg twice daily, 10 to 14 days. Safety and efficacy analyses in intention-to-treat (ITT) and evaluable populations. Three hundred three of 304 patients were included in the ITT and safety analyses and 260 (86%) were evaluable at the end of follow-up. Streptococcus pneumoniae was the cause of pneumonia in 62 (20%) patients (11 with bacteremia), Chlamydia pneumoniae in 40 (13%), and Mycoplasma pneumoniae in 38 (13%) patients. The success rates for Spfx and ROXI at the end of follow-up were 82% and 72%, respectively, in the ITT population, and 94% and 79%, respectively, in the evaluable population. The odds ratio Spfx/ROXI for success was 4.5 (95% confidence interval, 1.9, 10.8) for the evaluable population. Both drugs were, overall, equally safe. GI symptoms were the most common adverse experiences in bot...Continue Reading

References

Apr 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J P ThysB Byl
Mar 1, 1991·Antimicrobial Agents and Chemotherapy·N X ChinH C Neu
Apr 1, 1987·British Journal of Diseases of the Chest·M A Woodhead, J T Macfarlane
Jan 1, 1995·The Journal of Antimicrobial Chemotherapy·A Ortqvist
Mar 1, 1994·The Journal of Antimicrobial Chemotherapy·M Cruciani, D Bassetti
Jan 1, 1993·Scandinavian Journal of Infectious Diseases·B SundelöfS Darougar
Feb 1, 1994·Chest·B GitlerS D Buffa

❮ Previous
Next ❯

Citations

Nov 30, 2000·Current Infectious Disease Reports·P Ball
Oct 27, 1998·Lancet·P D Brown, S A Lerner
Aug 27, 1999·Clinical Therapeutics·J MorganrothG H Talbot
Feb 15, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D C Hooper
Jan 26, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joseph P Lynch III, Fernando J Martinez
Dec 4, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Victor L YuMiguel Sabria
Jun 20, 1998·BMJ : British Medical Journal·S J Wort, T R Rogers
Nov 20, 2001·Thorax·UNKNOWN British Thoracic Society Standards of Care Committee
Oct 6, 1999·Clinical Therapeutics·J MorganrothG H Talbot
Oct 13, 2006·Current Opinion in Infectious Diseases·L A Mandell
Aug 18, 1999·The American Journal of Medicine·P Ball
Feb 28, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·H. LodeA. Ortqvist
Apr 9, 1998·The Annals of Pharmacotherapy·S J MartinS L Pendland
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Walter A VolbergJun Zhou
Oct 11, 2014·The Cochrane Database of Systematic Reviews·Smita PakhaleLise M Bjerre
Oct 30, 1998·Postgraduate Medicine·R Gleckman, G De La Rosa
May 1, 1999·Postgraduate Medicine·R B Kohler
Sep 13, 2000·Drugs & Aging·D Lieberman, D Lieberman
Nov 28, 2002·The Annals of Pharmacotherapy·Alan R SalkindJohn W Foxworth
Sep 28, 1998·Biochimica Et Biophysica Acta·D C Hooper
Aug 20, 2003·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C CarbonP Decosta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.